Despite the initial efficacy of EGFR‐TKIs, approximately 65% of EGFR‐TKI‐sensitive NSCLC patients develop resistance to these medications within 9 to 13 months of treatment.137. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.